| Disease | 1200 MG OF CALCIUM SUPPLEMENT (NOT DEFINED) PER DAY.
RIMOSTIL EXERTS A SIGNIFICANT AND MARKED EFFECT ON HDL-C AND APOB, AND SELECTIVELY IMPROVES CORTICAL BONE DENSITY IN THE PROXIMAL RADIUS AND ULNA, BUT CAUSES NO ENDOMETERIAL THICKENING IN POST-MENOPAUSAL WOMEN. NOTE: EACH PATIENT ALSO RECEIVED
AND 3.31+-0.88; P=0.0002) COMPARED WITH BASELINE, AS WAS THE LDL/HDL RATIO (1.97+-0.78, 1.89+-0.7 AND 1.91+-0.72; P=0.01). NO SIGNIFICANT DIFFERENCES WERE OBSERVED BETWEEN THE DOSES. CONCLUSION: THE ISOFLAVONE DIETARY SUPPLEMENT
INCREASE IN HDL-C RELATIVE TO BASELINE (16.5+-17.2%, 28.6+-32.7%, 15.8+-18.2%; P=0.0001) AND A SIGNIFICANT DECREASE OF APOB (-10.6+-10.6%,-9.7+-14.3%-12.2+-11.5%; P<0.0001). THE TC/HDL RATIO WAS SIGNIFICANTLY LOWER (3.21+-0.84,3.39+-0.95
MONTHS. RESULTS: AT BASELINE, TC WAS 5.79+-0.82 MM,HDL-C 1.65+-0.28 MM. TC/HDL AND LDL/HDL WERE 3.75+-1.14 AND 2.32+-0.94 RESPECTIVELY. LIPID EFFECTS: AT ALL DOSES TESTED, TREATMENT WITH RIMOSTIL FOR 6 MONTHS RESULTED IN A SIGNIFICANT
6 MONTHS. TOTAL CHOLESTEROL (TC) HDL, CHOLESTEROL (HDL-C), LDL CHOLESTEROL (LDL-C),APOLIPOPROTEIN B (APOB), TC/HDL AND LDL/HDL WERE MEASURED AT 0,3,,6 AND 8 MONTHS. ENDOMETERIAL THICKNESS WAS MONITORED USING TRANSVAGINAL ULTRASOUND AT 0,3 AND 6
50 POST-MENOPAUSAL WOMEN WERE RANDOMLY ASSIGNED TO TREATMENT WITH 28.5, 57 OR 85.5 MG OF A NEW ISOFLAVONE DIETARY SUPPLEMENT (RIMOSTIL, NOVOGEN LIMITED) FOR 6 MONTHS, FOLLOWED BY 2 MONTHS OF PLACEBO WASHOUT. BONE DENSITY WAS MEASURED AT 0,3 AND |